Skip to main content

Table 1 Baseline characteristics and quality assessment of included studies

From: Oncological outcome of complete response after neoadjuvant chemotherapy for breast conserving surgery: a systematic review and meta-analysis

 

General information

NOS score

Author

Study design

Publish year

Country of enrolment

Neoadjuvant chemotherapy protocal

Total patients

Mean age (year)

Tumor size

Follow-up time (month)

Selection

Comparability

Outcome

Total score

Beriwal [24]

RS

2006

USA

CMF or AC or CAF or ACT in unclear cycle and interval time

153

52

T I,II,III,IV

60

3

1

2

6

Bonadonna [20]

CT

2002

Italy

Single-agent E 3 cycles every 3 weeks

317

49

T II,III

60

3

2

2

7

Caudle [19]

RS

2012

USA

Anthracycline-based or taxane-based or a combination of the two

595

51

T I,II,III,IV

64

3

1

2

6

Cho [22]

RS

2013

Korea

Unclear

431

49

T IV

46

2

1

2

5

Criscitiello [28]

RCT

2013

Spain

Paclitaxel with HER2-targeted therapy

455

NA

T II,III,IV

NA

3

2

2

7

Fastner [17]

RCT

2014

UAS

ED-based 3–6 cycles

107

48

T II,III

59

4

2

3

9

Jimbo [21]

RS

2015

Japan

4 cycles of AC or FEC followed by weekly T

315

50

T I,II,III,IV

61

3

1

2

6

Massidda [15]

CT

2007

Italy

PEV 6 cycles every 2 weeks

40

48

T IV

84

3

1

2

6

McIntosh [18]

RS

2003

England

CVAP* 4 or 6 cycles every 3 weeks

166

51

T II,III,IV

62

2

1

2

5

Noh [25]

RS

2014

Korea

AT or AC or T

260

46

T I,II,III,IV

66

2

1

2

5

Rouzier [10]

RS

2001

France

FAC or CMF or CTF or CE 4 cycles every 4 weeks

257

47

T I,II,III

93

3

1

2

6

Rouzier [14]

RCT

2004

France

Neoadjuvant epirubicin-based chemotherapy(AVCMF, FEC, FAC) 3–4 cycles at 21-day intervals or longer

589

50

T II,III

67

3

2

3

8

Shen [16]

RCT

2004

USA

Doxorubicin-based and paclitaxel-based

33

52

T IV

91

3

2

3

8

Von [27]

RCT

2008

Germany

TAC*6 or 8 cycles if response. TAC*2 if response then followed by another TAC 4 or 6 cycles, if not response then followed by NX or TAC 4 cycles

622

51.8

T I,II,III,IV

33

4

2

3

9

Walker [23]

CT

2011

England

AC 4 cycles every 3 weeks followed by weekly or every 3 weeks docetaxel

82

50

T II,III,IV

72

3

2

3

8

Yamazaki [26]

RS

2015

Japan

AT-based 4 cycles

217

52

T I,II,III,IV

84

3

1

2

6

  1. Abbreviation: RS retrospective study, RCT randomized clinical trial, CT clinical trial, A doxorubicin, T taxane-based drug, E epirubicin, D docetaxel, C cyclophoshamide, F 5-fluorouracil, M methotrexate, P cisplatin, V vincristine, P* prednisolone, X capecitabine, N vinorelbine, NA not available, NOS Newcastle-Ottawa Scale